ATHX
Athersys Inc (ATHX)
$0.24
Key Stats
$0.2406
Day's Range
$0.2661
$0.18
52-Week Range
$1.81
| Returns | |
| 1 month return | 18.89% |
| 3 month return | 55.35% |
| 1 year return | 83.52% |
| 5 year return | 83.52% |
Company Information
Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived 'off-the-shelf' stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization.
| Organization | Athersys Inc |
| CEO | Gil Van Bokkelen |
| Industry | Health Technology |
Analyst Recommendation
based on 10 analysts ratings
Buy
80%
Buy
20%
Hold
0%
Sell
Based on 10 Wall street analysts offering stock ratings for Athersys Inc(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 2300.0%Current
$0.25
Target
$6.0
Recommendation Trend
Based on 10 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 8 | 8 | 9 |
| Hold | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 |
| Consensus | BUY | BUY | BUY |
Company Financials
Highlights
| Market Capitalization | 119.0M |
| Book Value | 0.07 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0 |
| Earnings Share | -0.39 |
| PEG Ratio | -0.34 |
| Wall Street Target Price | 4.25 |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 0.63 |
| Price/Sales (ttm) | 21.58 |
| Price/Book (mrq) | 8.22 |
| Enterprise Value | 107.0M |
| Enterprise Value/Revenue | 19.4 |
| Enterprise Value/Ebitda | 0.0 |
Technicals
| Beta | -1.56 |
| 50 Day MA | 0.7 |
| 200 Day MA | 1.1 |
Institutional Holdings
BlackRock Inc
5.4%
Vanguard Group Inc
4.26%
Vahanian & Associates Financial Planning Inc.
1.99%
State Street Corporation
1.47%
Geode Capital Management, LLC
1.41%
JPMorgan Chase & Co
0.89%
